Minakshi Guha

Dr. Minakshi Guha is an accomplished PhD scientist with two decades of expertise in cancer genomics, next-generation sequencing, assay development, and clinical diagnostics. She earned her PhD from the University of Massachusetts Medical School, where she investigated transcriptional regulation of cancer cell survival mediated by tumor suppressors. Following this, she completed a postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School, where she developed novel methods for the early detection of low-abundance mutations in cancer.
Dr. Guha is widely recognized for her expertise in developing NGS assays, optimizing processes, and implementing advancements in clinical diagnostics. She currently contributes her skills to Takeda’s Oncology Precision & Translational Medicine function. At Takeda, she focuses on enhancing cancer biomarker detection methodologies to support personalized medicine and accelerate clinical development.
Before joining Takeda, Dr. Guha led numerous clinical development projects at Novartis, focusing on clinical biomarkers and companion diagnostics across solid tumors, rare diseases, neuroscience, and cardiovascular indications. She is a strong advocate for personalized medicine, minimally invasive diagnostic solutions, and liquid biopsy-based biomarker assays.